Recent Comments

Comment RSS

Ambien News and Research RSS Feed - Ambien News and Research

Computerized alerts induce clinicians to prescribe comparable generic equivalents

10. November 2009 02:48
Simple computerized alerts can help curb the impulse to prescribe unnecessarily expensive, heavily marketed drugs. A study in the August issue of Journal of General Internal Medicine found that when clinicians received computerized alerts, which compared medication brands, they changed 23.3 percent of prescriptions for four heavily marketed sleep medications to comparable generic equivalents. [More]

Posted in: Device / Technology News | Healthcare News

Tags: , , , , ,

USPTO issues Notice of Allowance to NovaDel Pharma

6. November 2009 01:01
NovaDel Pharma Inc., today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. Patent Application No. 10/671,715, entitled “Buccal, Polar and Non-polar Spray Containing Zolpidem,” which covers a method of treating insomnia by administering zolpidem to humans utilizing NovaMist™ Oral Spray spray technology. [More]

sanofi-aventis reports financial results for the third quarter of 2009

30. October 2009 08:59
In the third quarter of 2009, sanofi-aventis generated net sales of euro 7,400 million, up 8.0% on a reported basis. Exchange rate movements had a favorable effect of 2.0 percentage points, with the appreciation of the U.S. dollar (and to a lesser extent the yen) against the euro more than offsetting the unfavorable effects of some other currencies. [More]

Meda launches EDLUAR in the U.S.

9. September 2009 01:59
Meda Pharmaceuticals Inc. (Meda) today announced the commercial availability of EDLUAR(TM) (zolpidem tartrate sublingual tablets) in the United States. EDLUAR is indicated for the short-term treatment of insomnia characterized by difficulties with falling asleep. EDLUAR is the first available under-the-tongue formulation of zolpidem tartrate, which is the most prescribed treatment for insomnia. Zolpidem tartrate is also the active ingredient in Ambien(R) oral tablets. [More]

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , , ,

Nighttime acid reflux symptoms impair sleep quality

1. September 2009 04:09
There has been much debate about the relationship between gastroesophageal reflux disease (GERD) and sleep. Three new studies in Clinical Gastroenterology and Hepatology explore GERD's effect on sleep quality and the health-care system as well as how a widely prescribed sleeping pill may mask the disease. [More]

MRRI research study to investigate how zolpidem might restore consciousness for patients in the vegetative state

31. August 2009 10:47
Moss Rehabilitation Research Institute (MRRI), the research arm of MossRehab, one of the world’s leading clinical rehabilitation centers, has launched an ambitious research study to investigate how the sleep drug zolpidem might restore consciousness for patients in the vegetative state. [More]

Sharp increase in use of prescription sleep aids by young adults

19. January 2009 21:29
Use of prescription sleep aids nearly tripled among 18- to 24-year-olds between 1998 and 2006, according to a study released today by the Healthcare business of Thomson Reuters. [More]

Posted in: Medical Research News

Tags: , , , , , , ,

Save money wih generics

10. December 2008 21:18
Today, more than ever, consumers can opt for generic equivalents of brand-name medications at substantial cost savings. [More]

WSJ examines drugmakers' use of 'unbranded product advertising' to promote disease awareness, treatment options

1. September 2008 19:56
The Wall Street Journal on Friday examined "unbranded product advertising" for brand-name drugs, which allow drugmakers to drive television viewers to Web sites promoting drugs without the requirement of listing the products' side effects in the TV advertisement. [More]

Posted in: Pharmaceutical News

Tags: , , , , ,

Ranbaxy receives approval to manufacture Zolpidem tablets for insomnia

27. April 2007 21:59
Ranbaxy Laboratories Limited (RLL), has announced that the Company has received final approval from the U.S. Food and Drug Administration to manufacture and market Zolpidem Tartrate Tablets, 5mg and 10mg. [More]

Posted in: Pharmaceutical News

Tags: , , ,

Mylan anounces FDA approval of Zolpidem Tartrate tablets

24. April 2007 07:18
Mylan Laboratories has announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Zolpidem Tartrate Tablets, 5 mg and 10 mg. [More]

Posted in: Pharmaceutical News

Tags: , ,

FDA approves generic versions of Ambien

24. April 2007 07:06
The U.S. Food and Drug Administration (FDA) today approved the first generic versions of Ambien (zolpidem tartrate) immediate-release tablets. [More]

Posted in: Pharmaceutical News

Tags: , , , ,

Sedative-hypnotic drugs to get stronger warning labels

14. March 2007 14:29
The U.S. Food and Drug Administration (FDA) has requested that all manufacturers of sedative-hypnotic drug products, a class of drugs used to induce and/or maintain sleep, strengthen their product labeling to include stronger language concerning potential risks. [More]

Posted in: Pharmaceutical News

Tags: , , , ,

Prescription drug prices for U.S. residents ages 50 and older increased at about twice inflation rate

8. March 2007 04:09
Manufacturers' prices for the 193 prescription drugs most commonly used by U.S. residents ages 50 and older increased at about twice the rate of inflation in 2006, according to an annual report released on Tuesday by AARP, Cox/Atlanta Journal-Constitution reports. [More]

Posted in: Pharmaceutical News

Tags: , , , ,

FDA warns consumers about buying medications over the Internet

19. February 2007 06:22
The Food and Drug Administration (FDA) in the United States has again warned consumers about buying medications over the Internet. [More]

Posted in: Pharmaceutical News

Tags: , , , , , ,

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.